Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE129099 | GEO | 2019/07/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Project description: Not available

| S-EPMC6721800 | biostudies-literature

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy [ID8 and ID8-IP / KMF cells]

Project description:Gene copy number changes, cancer stem cell (CSC) increases, and platinum chemotherapy resistance contribute to poor prognosis in patients with recurrent high grade serous ovarian cancer (HGSOC). CSC phenotypes involving Wnt-b-catenin and aldehyde dehydrogenase activities, platinum resistance, and tumor initiating frequency are here associated with spontaneous genetic gains, including genes encoding KRAS, MYC and FAK, in a new murine model of ovarian cancer (KMF). Noncanonical FAK signaling was sufficient to sustain human and KMF tumorsphere proliferation, CSC survival, and platinum resistance. Increased FAK tyrosine phosphorylation occurred in HGSOC patient tumors surviving neo-adjuvant platinum and paclitaxel chemotherapy and platinum resistant tumorspheres acquired FAK dependence for growth. Importantly, combining a pharmacologic FAK inhibitor with platinum overcame chemoresistance and triggered apoptosis in vitro and in vivo. Knockout, rescue, genomic and transcriptomic analyses collectively identified more than 400 genes regulated along a FAK/b-catenin/Myc axis impacting stemness and DNA repair in HGSOC, with 66 genes gained in a majority of Cancer Genome Atlas samples. Together, these results support combinatorial testing of FAK inhibitors for the treatment of recurrent ovarian cancer.

2019-07-01 | GSE129097 | GEO

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

Project description:FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

| PRJNA530129 | ENA

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy [KMF parental, KMF clone KT13 (FAK-/-), KT13 + GFP-FAK, KT13 + GFP-FAK R454, and KT13 + deltaGSK beta-catenin]

2019-07-01 | GSE129098 | GEO

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy [ID8 and ID8-IP / KMF cells]

Project description:FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy [ID8 and ID8-IP / KMF cells]

| PRJNA530133 | ENA

Project description:FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy [KMF parental, KMF clone KT13 (FAK-/-), KT13 + GFP-FAK, KT13 + GFP-FAK R454, and KT13 + deltaGSK beta-catenin]

| PRJNA530132 | ENA

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts.

Project description: Not available

| S-EPMC6591669 | biostudies-literature

Acquired and intrinsic resistance in cancer immunotherapy.

Project description: Not available

| S-EPMC5528612 | biostudies-other

TR3 modulates platinum resistance in ovarian cancer.

Project description: Not available

| S-EPMC3944084 | biostudies-literature

ATP11B mediates platinum resistance in ovarian cancer.

Project description: Not available